Investors seemed to approve, as AbbVie's shares closed 1% higher on the news. The stock is up 33.68% over the past year, 18.68% YTD. Let’s look at what the charts indicate for AbbVie stock and ...

AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. The program also includes an ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

Chart Source: YCharts AbbVie has solidified its reputation among dividend-paying stocks, having increased its dividend by 265.1% since its inception in 2013. As a member of the S&P Dividend ...

Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

Thanks to the donation, the facility will be named the AbbVie Foundation Cancer Pavilion when it opens in 2027.

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...

AbbVie (NYSE:ABBV) said Botox Cosmetic, added with its $63B acquisition of Allergan in 2020, is the first and only product ...

(Reuters) - U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...